<DOC>
	<DOCNO>NCT00449423</DOCNO>
	<brief_summary>The primary objective study evaluate whether metabolic modulation improve hemodynamics outcome acute heart failure</brief_summary>
	<brief_title>Metabolic Modulation Treatment Acute Heart Failure</brief_title>
	<detailed_description>Acute heart failure serious disease despite modern therapy carry high mortality . Inotropic drug improve patient status yield high risk death . Previous study show myocardial contractility improve glucose fermentation regulate decrease Free Fatty Acids high . In placebo-controlled design wish shift myocardial substrate metabolism towards increase glucose uptake utilization measure hemodynamics biochemical marker metabolism prognosis .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Acipimox</mesh_term>
	<criteria>Acute heart failure NYHA class III IV . ejection fraction &lt; 35 Age &lt; 18 år &gt; 85 år , allergy renal failure recently develop brady tachyarrythmias Serious infection Heart failure due restrictive hypertrophic cardiomyopathy stenotic valvular heart disease Recent Myocardial infarction ( &lt; 6 Weeks ) Pulmonary Wedge pressure &gt; 30 mm Hg diabetes mellitus treat insulin peptic ulcer pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Acute heart failure</keyword>
	<keyword>Metabolic modulation</keyword>
</DOC>